InvestorsHub Logo

HadToHavit

06/05/17 9:45 PM

#8994 RE: HadToHavit #8993

Thanks Dr. Worth repeating... stockholders confidence @ $4.50

MONMOUTH JUNCTION, N.J., March 31, 2017 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced the pricing of an underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $4.50 per share, representing gross proceeds of approximately $10.0 million. In addition, CytoSorbents has granted the underwriters a 30-day over-allotment option to purchase up to 333,333 additional shares of common stock at the public offering price.